Avastin Alarm

| March 04, 2011
Talk about this article with nurses and others in the oncology community in the General Discussions Oncology Nursing News discussion group.
A meta-analysis of randomized controlled trials revealed treatment-related fatalities were 1.5 times higher for combination treatment with Avastin (bevacizumab) and chemotherapy versus chemotherapy alone. The review, which was published in the Journal of the American Medical Association, included 16 trials with 10,217 patients. Overall, treatment-related death occurred in 2.5% of the Avastin population. The authors maintain the potential survival benefits may still outweigh the fatality risk when evaluating treatment options. Avastin is FDA-approved for the treatment of colon, kidney, brain, and lung cancers; however, the agency is in the process of revoking its breast cancer indication.

Talk about this article with nurses and others in the oncology community in the General Discussions Oncology Nursing News discussion group.
External Resources

MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
TargetedOnc
OncNurse Resources

Blogs
Continuing Education
Discussions
Web Exclusives


About Us
Advertise
Advisory Board
Careers
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2017
Intellisphere, LLC. All Rights Reserved.